Dosimetric Evaluation of Two Multileaf Collimator Systems in Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Stage IIIC Cervical Cancer with Lymph Node Metastases - Top-Institutions - MDSpire

Dosimetric Evaluation of Two Multileaf Collimator Systems in Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Stage IIIC Cervical Cancer with Lymph Node Metastases

  • By

  • Hui Xiao

  • Ang Qu

  • Haitao Sun

  • Xile Zhang

  • Nan Zhang

  • Shuhua Wei

  • Xiuwen Deng

  • Chunxiao Li

  • Junjie Wang

  • Ping Jiang

  • April 23, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Radiation Oncology
    • Gynecologic Oncology
    • Medical Physics

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Radiation Oncology
    • Gynecologic Oncology
    • Medical Physics

  • #3

    Dana-Farber/Brigham and Women’s Cancer Center
    Dana-Farber/Brigham and Women’s Cancer Center

    Boston, MA

    Key Differentiators

    • Radiation Oncology
    • Gynecologic Oncology
    • Medical Physics

  • #4

    University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical Center

    Dallas, TX

    Key Differentiators

    • Radiation Oncology
    • Gynecologic Oncology
    • Medical Physics

  • #5

    Memorial Sloan Kettering Cancer Center - MSKCC
    Memorial Sloan Kettering Cancer Center - MSKCC

    New York, NY

    Key Differentiators

    • Radiation Oncology
    • Gynecologic Oncology
    • Medical Physics

Original Source(s)

Dosimetric Evaluation of Two Multileaf Collimator Systems in Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Stage IIIC Cervical Cancer with Lymph Node Metastases

  • by Hui Xiao, Ang Qu, Haitao Sun, Xile Zhang, Nan Zhang, Shuhua Wei, Xiuwen Deng, Chunxiao Li, Junjie Wang, Ping Jiang

  • April 23, 2026

Related Content

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Management of toxicities from antibody – drug conjugates in breast cancer